Evaluation of blood glucose in type II diabetic patients submitted to local anesthesia with different vasoconstrictors

• Autor(a) principal: MELLO,Renan Pollettini de
• Data de Publicação: 2016
• Outros Autores: RAMACCIATO,Juliana Cama, PERUZZO,Daiane Cristine, VICENTINI,Carllini Barroso, BERGAMASCHI,Cristiane de Cássia, MOTTA,Rogério Heládio Lopes
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: RGO - Revista Gaúcha de Odontologia (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1981-86372016000400425
• topic: Diabetes mellitus; Local anesthesia; Vasoconstrictors

ABSTRACT Objective: In the dental clinic, the use of local anesthetics containing vasoconstrictors in diabetic patients are still controversial raising some doubts. Thus, the objective of this randomized crossover clinical trial was to evaluate blood glucose, pulse oximetry and heart rate of type 2 diabetic patients when submitted to local anesthesia using prilocaine 3% associated to felypressin 0,03UI / ml (G1) and 2% lidocaine associated to epinephrine 1: 100,000 (G2). Methods: The sample consisted of 20 compensated type 2 diabetic patients (both genders) who were taking oral hypoglycemic drugs. The volunteers underwent two periodontal sessions (scaling) and one of the solutions tested was used in each visit. The cited parameters were evaluated at three different times: before the procedure (T1), 10 minutes after anesthesia (T2) and after 20 minutes (T3). Results: Regarding the blood glucose levels, no statistically significant difference was found in different times between G1 and G2 (p> 0.05). Similarly, regarding pulse oximetry and heart rate, no statistically significant differences were observed in intervals assessed between groups (p> 0.05), presenting values within normal limits. Conclusion: Considering the vasoconstrictors and the volume of anesthetic solution used, the results suggest that the evaluated vasoconstrictors do not alter significantly blood glucose, pulse oximetry and heart rate in compensated type 2 diabetic patients.